中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
7期
800-801
,共2页
糖尿病肾病%依帕司他%N-乙酰-β-D氨基葡萄糖苷酶%β2微球蛋白
糖尿病腎病%依帕司他%N-乙酰-β-D氨基葡萄糖苷酶%β2微毬蛋白
당뇨병신병%의파사타%N-을선-β-D안기포도당감매%β2미구단백
Diabetic nephropathies%Epalrestat%N-acetyl-β-D-glueosaminidase%B2一micmglobulin
目的 观察依帕司他对早期糖尿病肾病患者尿N-乙酰-β-D氨基葡萄糖苷酶(NAG)及β2微球蛋白(β2-MG)水平的影响,评价其对肾小管损伤的疗效.方法 将60例早期糖尿病肾病患者完全随机分为治疗组及对照组,各30例.对照组常规饮食控制、口服降糖药或胰岛素处理,治疗组在此基础上加用依帕司他50 mg,3次/d,治疗前和治疗12周后应用终点比色法测定尿NAG,免疫透射比浊法测β2-MG,苦味酸法测定尿Cr的变化.对2组各项检测结果进行对比与分析.结果 2组治疗前后差异无统计学意义(P>0.05).治疗组患者治疗12周后较治疗前尿NAG/Cr、β2-MG/Cr、mALB/Cr均明显降低,分别为(2.0B±0.79)U/mmol比(3.69±1.35)U/mmol、(0.098±0.070)ms/nunol比(0.179±0.101)mg/mmol、(6.00±2.20)mg/mmol比(7.93±2.01)mg/mmol,差异有统计学意义(P<0.05).结论 依帕司他可明显降低早期糖尿病肾病患者尿NAG及β2-MG水平,提示其能早期干预肾小管损伤,保护肾脏.
目的 觀察依帕司他對早期糖尿病腎病患者尿N-乙酰-β-D氨基葡萄糖苷酶(NAG)及β2微毬蛋白(β2-MG)水平的影響,評價其對腎小管損傷的療效.方法 將60例早期糖尿病腎病患者完全隨機分為治療組及對照組,各30例.對照組常規飲食控製、口服降糖藥或胰島素處理,治療組在此基礎上加用依帕司他50 mg,3次/d,治療前和治療12週後應用終點比色法測定尿NAG,免疫透射比濁法測β2-MG,苦味痠法測定尿Cr的變化.對2組各項檢測結果進行對比與分析.結果 2組治療前後差異無統計學意義(P>0.05).治療組患者治療12週後較治療前尿NAG/Cr、β2-MG/Cr、mALB/Cr均明顯降低,分彆為(2.0B±0.79)U/mmol比(3.69±1.35)U/mmol、(0.098±0.070)ms/nunol比(0.179±0.101)mg/mmol、(6.00±2.20)mg/mmol比(7.93±2.01)mg/mmol,差異有統計學意義(P<0.05).結論 依帕司他可明顯降低早期糖尿病腎病患者尿NAG及β2-MG水平,提示其能早期榦預腎小管損傷,保護腎髒.
목적 관찰의파사타대조기당뇨병신병환자뇨N-을선-β-D안기포도당감매(NAG)급β2미구단백(β2-MG)수평적영향,평개기대신소관손상적료효.방법 장60례조기당뇨병신병환자완전수궤분위치료조급대조조,각30례.대조조상규음식공제、구복강당약혹이도소처리,치료조재차기출상가용의파사타50 mg,3차/d,치료전화치료12주후응용종점비색법측정뇨NAG,면역투사비탁법측β2-MG,고미산법측정뇨Cr적변화.대2조각항검측결과진행대비여분석.결과 2조치료전후차이무통계학의의(P>0.05).치료조환자치료12주후교치료전뇨NAG/Cr、β2-MG/Cr、mALB/Cr균명현강저,분별위(2.0B±0.79)U/mmol비(3.69±1.35)U/mmol、(0.098±0.070)ms/nunol비(0.179±0.101)mg/mmol、(6.00±2.20)mg/mmol비(7.93±2.01)mg/mmol,차이유통계학의의(P<0.05).결론 의파사타가명현강저조기당뇨병신병환자뇨NAG급β2-MG수평,제시기능조기간예신소관손상,보호신장.
Objective To investigate the effect of epalrestat on urinary N-aeetyl-β-Glucosaminidase(NAG)and β2-Micmglobulin(β2-MG)excretion in patients at early stage of diabetic nephropathies.Methods Sixty patients were divided randomly into two groups;the control group and the treatment group were both treated witll dietary control and oral hypoglycemic drugs or insulin,meanwhile,the treatment group were treated with epalrestat 50 mg three times a day.Results There were no significant difference between control group and treatment group(P>0.05).Urinary NAG/Cr,β2-MG/Cr and mALB/Cr were decreased significantly in epalrestat treatment group after 12 weeks,which were(2.03±0.79)U/mmol vs (3.69±1.35)U/mmol,(0.098±0.070)mg/mmol vs(0.179±0.101)mg/mmol,(6.00±2.20)mg/mmol vs (7.93±2.01)mg/mmol(P<0.05).Condusion Epalrestat can decrease the levels of urinary NAG and β2-MG significantly,which showes that epalrestat can alleviate renal tubular injury.
